Clinical Trials
2 trialsNCT01664182 2022-06-07
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00467025 2016-03-23
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Amgen
Phase 2 Completed